Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT +3.03%41 3-Year EPS without NRI Growth Rate is 11.80% as of Jun. 2026, which is 138% above its 10-year median of 4.95. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.00 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 785 Drug Manufacturers companies, ADC Therapeutics ranks better than 54.65% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 11.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 17.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of ADC Therapeutics was 12.90% per year. The lowest was -20.60% per year. And the median was 4.95% per year.
ADC Therapeutics (NYSE:ADCT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
ADC Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ADCT vs BGM, CPIX, LFCR: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
ADC Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 11.80% mean?
ADC Therapeutics (ADCT) has a 3-Year EPS without NRI Growth Rate of 11.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for ADC Therapeutics and its competitors. This is 138% above median its historical median of 4.95. According to the industry distribution chart, ADC Therapeutics ranks #356 out of 785 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is ADC Therapeutics' 3-Year EPS without NRI Growth Rate too high?
ADC Therapeutics' current 3-Year EPS without NRI Growth Rate of 11.80% is 138% above median its 10-year median of 4.95. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.90. ADC Therapeutics' value of 11.80% is 19.2% above this industry median. Based on the distribution chart, ADC Therapeutics ranks #356 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' 3-Year EPS without NRI Growth Rate compare to BGM and CPIX?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #356 out of 785 companies for 3-Year EPS without NRI Growth Rate. This puts ADC Therapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.90. ADC Therapeutics' value of 11.80% is 19.2% above this benchmark. While the company's 10-year median is 4.95 vs. the industry median of 9.90, ADC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.90, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current 3-Year EPS without NRI Growth Rate of 11.80% is 19.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current 3-Year EPS without NRI Growth Rate is 11.80%, which is 138% above median its own 10-year median of 4.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.00, compared to a current price of $1.36 — trading 32% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 11.80%, which is 138% above median its 10-year median of 4.95 and 19.2% above the Drug Manufacturers industry median of 9.90. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current 3-Year EPS without NRI Growth Rate is 11.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.36 is trading 32% below its estimated GF Value™ of $2.00.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
3-Year EPS without NRI Growth Rate: 11.80% (138% above median its 10-year median of 4.95)
GF Value™: $2.00 vs. price of $1.36 (32% below fair value)
Industry Position: 19.2% above the Drug Manufacturers median (#356 of 785)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
